Respiratory
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pulmocide Grows Cash Pile For Promising Antifungal
The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.
C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion
GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.
Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
AstraZeneca’s Fasenra Future Weakened By Pivotal Eosinophilic Esophagitis Trial Flop
The major’s monoclonal antibody drug missed one of two primary endpoints in a late-stage eosinophilic esophagitis trial in the second setback this year to plans for label expansion beyond the asthma maintenance setting.
Verona Boosts Funds And Becomes Potential Takeover Target
The UK biotech is in a strong spot after extending its cash runway to prepare for the launch of ensifentrine, which analysts believe could become a pipeline-in-a-molecule for respiratory diseases.
Tezspire All Set To Tackle Big Biologic Rivals In Severe Asthma
With a European approval in the bag for Tezspire, AstraZeneca is looking for quick and successful launches of the severe asthma drug so it can mount a challenge to the other biologics in the space, notably Sanofi and Regeneron’s Dupixent.
Can Moderna Pull Off More Disruptive Innovation? Flu And RSV Shots Are Next Test
Moderna needs to develop new mRNA-based therapies beyond COVID-19, and flu and RSV will be the big readouts in 2023.
Verona Transformed After Phase III Victory For COPD Therapy
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.
AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost
The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.
GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial
GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.
Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.